Wealth management products: risk begins before the order

A product may pay its coupon as expected and still be difficult to explain, value or sell. On 3 June 2026, FINMA published a communication on risks observed in the use of products in individual portfolio management. The authority noted an increase in reported cases involving asset managers and stressed early risk identification, robust governance and the application of conduct rules with the client’s circumstances in mind. This article does not turn a supervisory communication into a blanket ban. It shows where a commercial choice becomes a governance decision : product selection, economic ties, remuneration, liquidity, concentration, suitability for the mandate and monitoring after purchase. The proposed first engagement is deliberately bounded: review a sample of products and portfolios, then classify gaps and actions. The acquisition opportunity is credible because authorised managers can be identified and the need can recur; it remains responsible only if no message implies that a particular firm or product is deficient. General analysis updated on 7 August 2026. It does not replace a decision by FINMA or a supervisory organisation, legal advice or an investment recommendation.

FINMA’s communication of 3 June 2026 describes risk patterns observed in the use of products in individual portfolio management and restates existing obligations. It stresses early risk identification, sound governance and application of conduct rules according to the client’s circumstances. It does not create a public list of products that are automatically prohibited.

FINMA states that the number of reported breaches has risen and that some cases have caused significant losses. It does not provide a rate that can be applied to all asset managers. Firms should therefore avoid two opposite errors: dismissing the signal because it is not a new law, or reviewing every account indiscriminately without a risk hypothesis.

A product may be lawfully distributed yet remain unsuitable for a client’s mandate, risk profile, time horizon or liquidity needs. Product compliance and appropriate use answer different questions. The review must preserve the reasoning that supported the decision and respond when either the product’s characteristics or the client’s circumstances change.

Concentration may be hidden across several positions linked to the same issuer, project or risk factor. Apparent liquidity may diminish when markets come under stress. Fees and relationships with connected parties may create a conflict that must be identified and addressed. No single indicator replaces an assessment of the whole picture.

The first diagnostic clients can buy is a sample review combining several complex or illiquid products with portfolios that hold them. It examines governance, product analysis, fit with the mandate, conflicts, client information and monitoring. It produces a classification of gaps and a remediation plan, but certifies neither the whole firm nor every past recommendation.

The partner defines the sample with the firm: proprietary or connected products, illiquid structures, concentrations, new offerings and cases requiring an exception. Data remains within an agreed environment. Price, depth and timing must be agreed before the campaign. A file requiring legal or actuarial expertise is escalated.

A conflict is identified by mapping issuers, distributors, connected persons, remuneration and benefits around the selection process. Its presence does not automatically establish a breach: the firm must identify, avoid or manage it under the applicable framework and disclose it where required. Outreach addresses controls and evidence, never presumed intent.

A matrix of economic relationships makes the control easier. It includes proprietary products, retrocessions, distribution agreements and relevant personal relationships under the internal policy. The partner collects only the information needed and assigns sensitive decisions to the appropriate responsible person.

The analysis should be reopened when a material characteristic, counterparty, liquidity profile, valuation, remuneration arrangement or client circumstance changes. A recurring exception or new concentration may also trigger review. A fixed timetable complements these events; it should not be the only monitoring mechanism.

How to read the diagram. The review does not prejudge an exit. It makes the decision visible, assigned and traceable.

The pool includes authorised asset managers, trustees where relevant to their activities, management teams and compliance providers that use or oversee products. Signals include a new range, acquisition, change of custodian, rapid growth or a control-function hire. The FINMA list identifies institutions, not firms presumed to be in breach.

Search-led content explains the communication and its implications. Professional networks and supervisory organisations provide context. Direct contact follows a professional signal and offers a sample review without referring to a loss, product or client. Before activation, the partner confirms its own conflicts, capacity and engagement limits.

After the midpoint of this article, the wealth management market page connects this review with FinSA, AMLA and AEOI. These topics share governance concerns, but not the same first purchase: here the diagnostic covers products and their use; the others address authorisation, due diligence or tax reporting.

Value is measured through diagnostics commissioned, gaps closed, time to decision and cycles renewed, with the partner’s agreement. It is not measured by products reported or hypothetical losses avoided. Portfolio data and actual results remain confidential; demonstrations use only scenarios expressly identified as illustrative.

The margin on the initial diagnostic must be calculated before a campaign starts. If the sample requires too much unpredictable specialist input, the service must be divided into clearer components. Commercial reporting distinguishes meetings, proposals, paid engagements and cash collected.

A review becomes recurring when a new product enters the approved universe, an event triggers a control or a periodic sample tests the framework. Every cycle must reach a conclusion and close actions. Vague monitoring without a defined population or threshold does not justify continuing fees.

FINMA provides the June 2026 signal and observed risk patterns; FinSA and its ordinance establish the conduct rules; supervisory organisations oversee the managers concerned. These sources clarify the obligations. They do not publicly assess any portfolio, recommend a product or quantify an advisory engagement.

Official links and dates remain in the private research file. This article names the authorities without external links. Before any campaign, the partner rechecks the texts, the scope of the institutions concerned and its own independence.

The complimentary eligibility test examines your expertise, independence, initial sample, acquisition challenge and ability to work securely. It does not approve any product. It determines whether getfishnet and your team can build a tailored strategy around an identifiable, recurring professional need without exposing end-client data.